Monika Fischer, MD, MS, FACG, AGAF, is an associate professor of medicine and director of the IBD Program at Indiana University School of Medicine in Indianapolis, IN. Dr Fischer received her medical degree from Semmelweis University in Budapest, Hungary. After completing her training in internal medicine and gastroenterology, she moved to the United States and worked as a postdoctoral fellow at Indiana University. She then completed fellowships in gastroenterology and inflammatory bowel diseases (IBD) at Indiana University, earned her master of science in clinical science degree, and joined Indiana University Health as faculty. Dr Fischer is board certified in internal medicine and gastroenterology. Dr Fischer recognized the magnitude of C. difficile-related harm early in her career as a healthcare provider to many patients with IBD. She has built and is currently directing the Fecal Microbiota Transplant Program, which has successfully treated over 700 patients. Her research focuses on outcomes of fecal microbiota transplantation in C. difficile infection with emphasis on severe therapy refractory cases.

Indianapolis, IN

 https://www.ncbi.nlm.nih.gov/myncbi/14CLxHG5c5x5y/bibliography/public/

 Dine Study (University of Pennsylvania), Celgene (RPC01-3202, 3202, 3204) , SERES Eco-Reset, Tour Study (University of North Carolina), FMT Database, ICON & ICON 2 Study (Brigham & Women’s Hospital), AGA FMT National Registry, Finch Therapeutics PRISM 3 CDI Trial & Extension, Eli Lilly Serenity Trial, Medtronic BLINK Study